Lund University:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lund University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5164
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lund University (LNU) is an educational service provider that offers master and bachelor programmes. It offers education and research in the areas of engineering, economics and management, science, law, social sciences, medicine, humanities, theology, fine art, music and others. The university spans its expertise in cancer research, neuroscience and neurodegenerative diseases, diabetes, stem cell therapy, epidemiology, Middle Eastern studies, materials science, and nanotechnology among others. It works in collaboration with other universities through international networks, cooperation platforms for research and education. LNU is headquartered in Lund, Sweden.

Lund University – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lund University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lund University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lund University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lund University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lund University, Medical Devices Deals, 2012 to YTD 2018 10
Lund University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lund University, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
RhoVac Enters into Research Agreement with Lund University 12
Rocket Pharma Entered into Research and Development Agreement with Lund University 13
Licensing Agreements 14
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 14
Avrobio Enters into Licensing Agreement with Lund University 15
Equity Offering 16
Akuru Pharma Spin Out from Lund University 16
Lund University – Key Competitors 17
Lund University – Key Employees 18
Lund University – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 20
Recent Developments 21
Government and Public Interest 21
Aug 29, 2018: Lund University research group receives follow-on DKK 1 million grant from Novo Nordisk Foundation for diabetes-related studies with Follicum peptides 21
Aug 22, 2018: New method grows brain cells from stem cells quickly and efficiently 22
Aug 21, 2018: Powerful molecules provide new findings about Huntington’s disease 24
Apr 18, 2018: Similarity between high-risk atherosclerotic plaque and cancer cells discovered 26
Apr 16, 2018: Hope for new treatment of severe epilepsy 27
Apr 09, 2018: Jan Sundquist at Lund University awarded an ERC Advanced Grant 28
Apr 06, 2018: Mechanism vital to keeping blood stem cells functional uncovered 29
Apr 03, 2018: Breakthrough for dangerous blood transfusion-related disease 30
Mar 02, 2018: Paradigm shift in the diagnosis of diabetes 31
Nov 30, 2017: Prestigious ERC grants awarded to Lund researchers 33
Nov 28, 2017: Molecular profiling of melanoma tumours explains differences in survival after T cell therapy 35
Nov 06, 2017: Helmsley Charitable Trust Awards $52 Million to Support the Global Platform for the Prevention of Autoimmune Diabetes 37
Nov 02, 2017: New research shows where in the brain the earliest signs of Alzheimers occur 39
Oct 25, 2017: New method helps rule out heart valve infection 41
Oct 05, 2017: Discovery of a new fusion gene class may affect the development of cancer 42
Sep 27, 2017: Grants to 18 research projects that may lead to future scientific breakthroughs 43
Jan 30, 2017: Unique mapping of methylome in insulin-producing islets 47
Product News 48
Jun 25, 2018: Fluorescent molecules reveal how cancer stem cells are selectively inhibited 48
May 29, 2017: New test method aims to predict allergenic potency of chemicals 49
Mar 12, 2018: New treatment for aggressive breast cancer 50
Mar 12, 2018: Aggressive breast cancer can be transformed into a treatable form 51
Other Significant Developments 52
Feb 06, 2017: An Innovative Medicines Initiative Project for Precision Medicine in DKD 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Lund University, Pharmaceuticals & Healthcare, Key Facts 2
Lund University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lund University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lund University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lund University, Deals By Therapy Area, 2012 to YTD 2018 9
Lund University, Medical Devices Deals, 2012 to YTD 2018 10
Lund University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
RhoVac Enters into Research Agreement with Lund University 12
Rocket Pharma Entered into Research and Development Agreement with Lund University 13
Novo Nordisk Enters into Research and Licensing Agreement with Lund University 14
Avrobio Enters into Licensing Agreement with Lund University 15
Akuru Pharma Spin Out from Lund University 16
Lund University, Key Competitors 17
Lund University, Key Employees 18
Lund University, Other Locations 19
Lund University, Subsidiaries 19
Lund University, Joint Venture 20

List of Figures
Lund University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lund University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lund University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lund University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lund University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lund University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lund University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lund University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lund University, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Lund University:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Datron World Communications, Inc.:企業の戦略・SWOT・財務分析
    Datron World Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Datron World Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Cyclo Therapeutics Inc (CTDH):企業の財務・戦略的SWOT分析
    Summary Cyclo Therapeutics Inc (Cyclo Therapeutics), formerly CTD Holdings Inc, is a biotechnology company that develops and manufactures cyclodextrin-based drugs. It is investigating Trappsol Cyclo, an orphan drug against Niemann-Pick disease type C and Alzheimer’s disease. The company also develop …
  • MYR Group Inc (MYRG):企業の財務・戦略的SWOT分析
    Summary MYR Group Inc (MYR Group) is an electrical contractor that provides specialty contracting services for industrial, commercial, and electrical infrastructure markets. The company operates substations, transmission lines, and distribution systems. It offers services such as distribution constr …
  • Evonik Industries Ag
    Evonik Industries Ag - Strategy, SWOT and Corporate Finance Report Summary Evonik Industries Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Okklo Life Sciences BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Okklo Life Sciences BV (Okklo) is a biopharmaceutical company that develops novel therapeutic solutions. The company offers cyclodextrin-based medicines for the treatment of neglected and orphan diseases. It also develops therapeutics for infectious diseases and lysosomal storage diseases. O …
  • DURECT Corp (DRRX)-医療機器分野:企業M&A・提携分析
    Summary DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company’s …
  • Kallpa Generacion SA:企業の発電所・SWOT分析2018
    Kallpa Generacion SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employee …
  • Dynacq Healthcare Inc (DYII):企業の財務・戦略的SWOT分析
    Summary Dynacq Healthcare Inc (DHI) is a healthcare consulting organization that provides surgical services. The organization develops and manages general acute hospitals that provide general surgeries. Its hospitals are designed to handle operations such as orthopaedics, neurosurgery and general su …
  • Texas Instruments Inc.:企業の戦略・SWOT・財務分析
    Texas Instruments Inc. - Strategy, SWOT and Corporate Finance Report Summary Texas Instruments Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • ResCare Inc:企業の戦略的SWOT分析
    ResCare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Tecpetrol SA:企業の戦略的SWOT分析
    Tecpetrol SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • HITT Contracting Inc:企業の戦略的SWOT分析
    HITT Contracting Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • CoreRx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CoreRx Inc (CoreRx) is a contract development manufacturing organization that provides a comprehensive range of drug development services. The company provides products portfolio such as oral, topical, liquids or parental, ophthalmic and combined medicines, among others. It provides a wide r …
  • CAP S.A.:企業の戦略・SWOT・財務情報
    CAP S.A. - Strategy, SWOT and Corporate Finance Report Summary CAP S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Kellogg Co:企業のM&A・事業提携・投資動向
    Kellogg Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kellogg Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Daniel Thwaites Plc:戦略・SWOT・企業財務分析
    Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report Summary Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • RayBiotech Inc-製薬・医療分野:企業M&A・提携分析
    Summary RayBiotech Inc (RayBiotech) is a life science company that offers proteins, antibodies and immunological kits. The company’s products include antibody arrays, elisa, functional assays, antibodies and custom recombinant protein service. It provides services such as testing services, custom se …
  • SK Innovation Co Ltd (096770):石油・ガス:M&Aディール及び事業提携情報
    Summary SK Innovation Co Ltd (SK Innovation) is an integrated energy and petrochemical company. It explores for and produces crude oil and natural gas; transportation of crude oil; and production of oil products such as gasoline and diesel. Through subsidiaries, the company carries out refining oper …
  • AISIN SEIKI Co., Ltd.:企業の戦略・SWOT・財務情報
    AISIN SEIKI Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AISIN SEIKI Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bionomics Ltd (BNO)-製薬・医療分野:企業M&A・提携分析
    Summary Bionomics Ltd (Bionomics) is a biopharmaceutical company that focuses on the development of treatments for cancer, and central nervous system disorders such as anxiety, depression and Alzheimer's disease. Its pipeline products include BNC210, BNC 105, BNC101, and BNC375. The company uses var …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆